Sign in Subscribe
Biochemistry

Novel Biomarker for Immunotherapy in Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Researchers from Tongji University have discovered a new biomarker for predicting the response to immunotherapy in non-small cell lung cancer (NSCLC). By analyzing the correlations between MED12 nonsynonymous mutations and survival, clinical, genomic, transcriptomic information, and immune infiltration information, the team identified MED12 as a significant predictor of immunotherapy outcome. The study found that MED12 mutations were associated with increased CD8 + T cell cytotoxicity, which is crucial for the success of immunotherapy.

Key Takeaways:

  • MED12 nonsynonymous mutations are associated with improved survival in patients with NSCLC undergoing immunotherapy.
  • MED12 is an independent and valuable biomarker for predicting the response to immune checkpoint inhibitor (ICI) therapy in NSCLC.
  • The study found that MED12 mutations modulate CD8 + T cell cytotoxicity via the STAT1/TAP2 axis.
  • The research used data mining across multiple datasets, including MSKCC, Naiyer2015, and TCGA datasets.
  • The study concluded that MED12 mutation is a significant predictor of immunotherapy outcome in NSCLC patients.

The study, published in Functional & Integrative Genomics, detailed the following statistics:

Statistics:

  • The study analyzed correlations between MED12 nonsynonymous mutations and survival, clinical, genomic, transcriptomic information, and immune infiltration information across multiple datasets (N = 879).
  • The research found that MED12 mutations were significantly associated with increased CD8 + T cell cytotoxicity (p < 0.01).
  • The study used luciferase assay, Western blot, ChIP-PCR, and siRNA to investigate the mechanism of MED12.
  • The research concluded that MED12 mutation is an independent and valuable biomarker for predicting the response to ICI therapy in NSCLC patients.

Sources:

  • MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer. Functional & Integrative Genomics, 2025;25(1):182.

Functional & Integrative Genomics can be contacted at: Springer Heidelberg, Tiergartenstrasse 17, D-69121 Heidelberg, Germany.

  • Researchers from Tongji University Report on Findings in Non-Small Cell Lung Cancer (MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer). Cancer Weekly. September 16, 2025; p 6827.

Read more